INTRODUCTION
Inhibitor of growth 4 (Ing4) is a member of the inhibitor of growth family of candidate tumor suppressor genes of which five have been identified in humans.
1,2 Downregulation of Ing4 has been reported in head and neck squamous cell carcinoma (SCC), breast cancer, melanoma and glioma, and its loss correlates with increased vascularization and more aggressive tumor growth. 3--6 Various tumor suppressor functions have been described for Ing4, including inhibition of cell proliferation, increased apoptosis, suppression of angiogenesis-related genes, and regulation of cell motility and spreading, and this diverse spectrum of activities suggests a potential gene therapy role for Ing4 in cancer treatment. 1, 2 Indeed, growth suppression via cell cycle arrest and apoptosis both in vitro and in vivo in a number of different cancer cell lines has been reported using a non-oncolytic adenovirus expressing Ing4. 7--10 Ing2 and Ing3 have also demonstrated the ability to induce cell cycle arrest and apoptosis but their designations as tumor suppressor genes is not as welldocumented as Ing4. Downregulation of both has been reported in SCC and cutaneous melanoma, but Ing2 overexpression has been reported in colorectal and cervical cancer and in Burkitt lymphoma. 11 The selective replication of the herpes simplex virus type 1 (HSV-1) variant HSV1716 for human tumor cells has great potential as an anticancer treatment. HSV1716, which lacks the ICP34.5 gene, has significantly reduced lethality in mice but replicates as efficiently as wild-type virus in actively dividing tissue culture cells. 12, 13 ICP34.5 is a neurovirulence factor proposed to condition post-mitotic cells for viral replication, via an interaction with proliferating cell nuclear antigen.
14,15 HSV1716 fails to replicate in terminally differentiated cells but its lytic replication destroys dividing cells and this has proved to be an effective oncolytic strategy. Phase 1 clinical trials have demonstrated the safety of intratumoral injection of HSV1716 in patients with recurrent glioma, metastatic melanoma and head and neck squamous cell carcinoma, and proof of principle of selective replication within tumors has been obtained. 16--20 The efficacy of oncolytic viruses can be enhanced by arming them with additional functions that complement their oncolytic activity such that expression of the gene therapy adjunct is disseminated efficiently throughout the tumor. Expression of antiangiogenic factors as gene therapy adjuncts to oncolytic viruses has attracted considerable interest especially as oncolytic HSV has been reported to induce angiogenesis in a glioma model. 21 Expression of angiogenic inhibitors will not only suppress this but add to the oncolytic potency of the virus by inhibiting tumor vascularization and enhanced efficacy, and angiogenesis inhibition by oncolytic HSV expressing human platelet factor 4, mouse endostatin and mouse interleukin 12 have been reported. 22--24 We report on an HSV1716 variant expressing Ing4 (HSV1716Ing4) initially conceived as an armed variant capable of Ing4-mediated suppression of angiogenesis. However, we identify a novel role for Ing4 in enhancing HSV1716 tumor destruction. Specifically, Ing4 improved the output of progeny during infection of tumor cells both in vitro and in vivo and, crucially, although Ing4 expression conferred this growth advantage to HSV1716 in human tumor cells, it did not compromise its selectively replication-competent phenotype.
MATERIALS AND METHODS

Cells and viruses
BHK, Vero and NIH 3T6 cells were grown as previously described. 25 Human ovarian cancer cell lines CP70, SKOV3, A2780 and Ovcar-3, human breast  cancer cell lines MCF-7, MDA-MB-361 and MDA-MB-468, the human A431  SCC, the human PC3 prostate cancer, the human SW480 colorectal  carcinoma and human UVW glioma cell lines were obtained from ATCC/ LGC Promochem, London, UK, and were cultured in DMEM/F12 medium supplemented with 10% NCS.
Production of HSV1716 variant expressing Ing4
Primers for the PCR amplification of Ing4 were designed using the human Ing4 sequence deposited in the NCBI database (Accession No. NM016162). The sense primer 5 0 -GAGAATTCGCGGCCGCGATGGCTGCGGGGATGTA TTTG-3 0 hybridizes at the ATG start codon of Ing4 (in bold) and incorporates EcoR1 and Not1 restriction sites (underlined) upstream of the translation start site. The antisense primer 5 0 -AGTCTAGACTCGAGCTAT TTCTTCTTCCGTTCTTGGGA-3 0 hybridizes downstream from the TAG stop codon of Ing4 (Ing4 sequence in bold) and incorporates Xho1 and Xba1 sites (underlined). PCR was performed using an initial denaturation at 94 1C for 4 min followed by 30 cycles of 94 1C for 30 s, 55 1C for 1 min and 72 1C for 2 min with a final extension step at 72 1C for 5 min. The c750 bp complementary DNA (cDNA) encoding Ing4 was successfully amplified from a placental cDNA library (AMS Biotechnology (Europe), Abingdon, UK) and the PCR product was ligated into the pGEM-Teasy vector (Promega, Southampton, UK) and sequencing confirmed a 100% match with NM016162. The PCR product was then ligated into the mammalian expression vector pcDNA4-myc-His (Invitrogen, Paisley, UK). The Ing4 expression cassette that included the CMV-IE promoter from plasmid was then transferred into the RL1 shuttle vector, pRL1-del/gfp, used for the production of HSV1716 variants by homologous recombination. 26 The presence of the Ing4 expression cassettes in the RL1 loci of HSV1716 was confirmed by both Southern blotting and by PCR using primers that amplify across the ICP34.5-deleted region of HSV1716 (data not shown). To confirm Ing4 expression, BHK cells were infected with 1 PFU (plaqueforming unit) per cell HSV1716Ing4 and, after 24 h, whole-cell extracts were analyzed by SDS-PAGE/western blotting using an Ing4 antibody (Abcam, Cambridge, UK). A 29 kDa protein was detected in the cells infected with HSV1716Ing4 but no endogenous Ing4 was detected in the mock-infected BHK cells or in other uninfected Vero, A431, Ovcar3, PC3 and SW480 cell extracts (data not shown). Unless stated otherwise, the HSV1716Ing4 variant created by homologous recombination was used in all in vivo and most in vitro studies.
HSV1716 variants in which Ing4 expression is controlled by different HSV promoters
Four additional HSV1716 variants in which Ing4 expression was controlled by the CMV-IE and the HSV-1 TK, gC and UL38 promoters were created using the HSV1716 GateRed site-specific recombination system. 26 The gC promoter was amplified from HSV-1 DNA by PCR as a SacI/KpnI fragment using primers (RE site in bold, promoter sequence underlined), 5 0 -GTGAGCTCCCGAAGACCGCCGGTGTG-3 0 and 5 0 -AGGGTACCGGCAAAGCGA GACCGGG-3 0 . The TK promoter was amplified from HSV-1 DNA by PCR as a SalI/PstI fragment using primers 5 0 -AGAAGTCGACTATGATGACACAA ACCCCGCC-3 0 and GACTGCAGTGCGGCACGCTGTTGACGCT-3 0 . The UL38 promoter was amplified from HSV-1 DNA by PCR as an EcoRI/SacI fragment using primers 5 0 -GGCCGAATTCGTGGGTTGCGGACTTTCTGC-3 0 and 5 0 -GGC CGGTACCACACTCACGCAAGGCGGAAC-3 0 . The appropriately digested UL38, gC or TK promoter DNAs were ligated into the plasmid SP73 (Promega) to create the vectors UL38p73, gCp73 and TKp73. The UL38/TK/ gC promoter DNAs were then exchanged with the CMV promoter of plasmid pcDNA4/myc-His to generate plasmids UL38pDNA4, gCpDNA4 and TKpDNA4. Ing4 DNA was ligated into each vector, and the TKp-Ing4, gCp-Ing4, UL38p-Ing4 and CMV-Ing4 expression cassettes were cloned into the customized Gateway entry vector pENT1Agfp for production of recombinant HSV1716 variants by site-specific recombination. 26 Temporal expression of Ing4 by CMV-Ing4, TK-Ing4, gC-Ing4 or UL38-Ing4 was confirmed by reverse transcriptase PCR using RNA extracted from infected BHK cells and the original Ing4 primers. Strong Ing4 expression was observed with CMV-Ing4 at 3 h post infection and this was maintained at 6 and 9 h post infection. In contrast, Ing4 expression was weak at 3 h after infection with TK-Ing4, gC-Ing4 and UL38-Ing4 and, although levels increased at 6 and 9 h, they were still less than CMV-Ing4. Actin reverse transcriptase PCR confirmed equal template amounts were used (data not shown).
Production of HSV1716 variants expressing Ing2 or Ing3
Ing2 and Ing3 cDNAs were amplified from the human placenta cDNA library using primer pairs for either Ing2 (for sequence used see CCDS3833.1;.
sense
0 -BamHI/NotI and 3 0 -XbaI/XhoI (underlined) restriction sites into the amplified fragments for direct cloning into pcDNA4. The CMV-Ing2 or CMVIng3 expression cassettes from their respective pcDNA4 constructs were excised and cloned into the customized Gateway entry vector pENT1Agfp used for production of recombinant HSV1716 variants by site-specific recombination. 26 
Production of HSV1716 variants expressing mutant Ing4
Ing4-deleted variants were generated by PCR using the pcDNA4 plasmid with the intact Ing4 DNA as template. For Ing4delC, primer pairs 5 0 -GGAATTCGATGGCTGCGGGGATGTATTTGG-3 0 and 5 0 -GCCTCGAGCAACA-CATCAGAGGGGTGGACACTGCC-3 0 amplified codons 1--204 of Ing4 as an EcoRI/XhoI fragment that was cloned into pcDNA4-myc-His. The missing codons (205--249) encode the plant homeodomain (PHD) domain of Ing4.
For Ing4delNLS, DNAs encoding separate N-and C-terminal domains were PCR amplified and linked to generate a DNA fragment lacking codons 131--178 thus deleting the conserved nuclear localization signal (NLS) coding region. The N-terminal encoding DNA was amplified using primer pairs 5 0 -GGAATTCGATGGCTGCGGGGATGTATTTGG-3 0 and 5 0 -CCTCGAGC GCGGCCGCCTTTTTGCCTTTGCTGGAAGAGCT-3 0 that incorporate 5 0 EcoRI/ 3 0 NotI restriction sites for cloning into pcDNA4. The C-terminal-encoding DNA was amplified as a 5 0 NotI/3 0 XhoI fragment using primer pairs 5 0 -GGAATTCGCGGCCGCGATGGGCAGTGTCCACCCCTCTGATGTGTTG-3 0 and 5 0 -CGCTCGAGTTTCTTCTTCCGTTCTTGGGAGCA-3 0 and ligated into the pCDNA4 construct already containing the N-terminal-encoding DNA. The resulting DNA encodes N-and C-terminal domains of Ing4 with an Ala-AlaAla-Met linker replacing the NLS. An additional full-length Ing4 DNA was amplified using the sense primer for Ing4delC and the antisense primer used for the C-terminal-encoding domain of Ing4delNLS and cloned into pcDNA4-myc-His. As the natural Ing4 stop codon is absent, the 6-His and Myc tags encoded from the pCDNA4 vector will be incorporated into all three expressed proteins. Ing4delC, Ing4delNLS and intact Ing4 expression cassettes from their respective pcDNA4 constructs were excised and cloned into the customized Gateway entry vector pENT1Agfp for production of recombinant HSV1716 variants by site-specific recombination. 26 To confirm the expression, BHK cells were infected with 1 PFU per cell HSV1716 variants expressing Ing4, Ing4delC and Ing4delNLS and, after 24 h, whole-cell extracts were analyzed by SDS-PAGE/western blotting using an anti-Myc tag antibody (Invitrogen). The 29 kDa Ing4 and appropriately sized Ing4delC and Ing4delNLS proteins were detected in the infected cell extracts and these were absent from mock-infected cells (data not shown).
plated out in 60 mm dishes and after 24 h they were infected with B1000 PFU HSV-1 17 þ , HSV1716 or HSV1716Ing4. The dilutions of each virus preparation used for these infections were titrated on BHK cells to confirm accurately the amounts of input virus. Each virus infection on each cell type was performed in quadruplicate at least. After 72 h of infection, cells and medium were harvested, subjected to one freeze/thaw cycle (À70 1C) and titrated on BHK cells. The results are reported in yields of progeny after 72 h of infection/input infectious virus with statistical comparisons made using analysis of variance.
Production of stable cell lines expressing ING4
To generate HSV1716Ing4, the Ing4 cDNA was initially cloned into the mammalian expression plasmid pcDNA4/myc-HisA (see above) and this Ing4 expression vector was used to create BHK, Vero or UVW cell lines that constitutively express Ing4. Cells were transfected with 100 mg of the Ing4 expression vector or with the empty pcDNA4-myc-HisA plasmid, and individual clones were isolated by limiting dilutions. 26 Ing4 expression was confirmed by reverse transcriptase PCR using the Ing4 primers and conditions described above. Three or four stable Ing4 or pcDNA4 clones of each cell type were expanded and maintained in appropriate medium containing 0.5 mg ml À1 zeocin. Each of the clones was plated out in 60 mm dishes in medium without zeocin, and after 24 h they were infected with 10 PFU (BHK) or 100 PFU (Vero or UVW) HSV1716. After 72 h of infection, cells and medium were harvested, subjected to one freeze/thaw cycle (À70 1C) and titrated on BHK cells. The results are reported in yields of progeny after 72 h of infection/input infectious virus, and Student's t-test comparisons were made between zeocin-resistant Ing4-and non-Ing4-expressing lines. Although attempts were made to isolate zeocin-resistant A431, MDA-MB-468, CP70 or Ovcar-3 cell lines expressing ING4, these were unsuccessful, and low transfection efficiencies, zeocin hypersensitivity or toxicity resulting from ING4 over-expression were probably responsible for this failure (data not shown).
In vivo tumor reduction studies
All animal procedures were performed under license from the UK Home Office. Female 6--8-week-old athymic nude mice (Charles River Labs, Tranent, UK) were maintained under specific pathogen-free conditions, and all animal experiments were performed according to the appropriate UK guidelines. Actively growing A431, CP70 or MDA-MB-468 cells were harvested and, after resuspension in PBS, 1 Â 10 6 cells per mouse were injected subcutaneously. When tumors reached 5 mm in diameter, the mice were injected either intratumorally or intravenously via the tail vein with PBS, HSV1716 or HSV1716Ing4. Mice were inspected most days post treatment, when tumor diameters reached 15 mm they were killed and, in some instances, the tumor xenograft was removed for analysis. The viral load in tumors and various organs was assessed by plaque-forming assay on BHK cells. Extracted intact tumors/organs were frozen immediately at À70 1C and, after thawing, the tissues were mechanically homogenized in a Retsch homogenizer (Castleford, UK) in 1 ml PBS before titration. DNA was then extracted from the remaining tissue using a Wizard SV genomic DNA kit (Promega) and Ing4 and HSV-1 gD PCRs were performed. Semiquantitative Ing4 PCR was performed using the primers and conditions described for the initial amplification of Ing4 cDNA. The semiquantitative HSV-1 gD PCR is highly sensitive and capable of detecting very low levels of HSV DNA (data not shown). Primers and PCR conditions are described elsewhere. 26 
RESULTS
Propagation of HSV1716Ing4 on different cell lines
Representations of the various ING proteins used for virus production are presented in Figure 1 . The replication of HSV1716Ing4 in tissue culture in a variety of different human cancer cell lines was investigated and compared with wild-type HSV-1 17 þ and parental unmodified HSV1716. Cell lines CP70, Ovcar-3, A2789, SKOV3, MCF-7, MDA-MB-468, MDA-MB-361, A431, PC3 and SW480 were infected at low multiplicities of infection and whole cells plus medium were harvested after 72 h. Yields (number of output progeny/input virus) for each virus in each cell type were determined and results are presented graphically in Figure 2 . Yields varied widely among the different cell types ranging from c1000 PFU/input virus in CP70 cells to c200 000 PFU/ input virus in MDA-MB-361 and Ovcar-3 cells. Propagation in MDA-MB-361, Ovcar-3, PC3 or SW480 cells generated similar yields of HSV1716 or HSV-1 17 þ , but in each of these cell types HSV1716Ing4 produced significantly higher yields of progeny. Propagation of HSV1716 was significantly reduced in A2780, SKOV3, CP70, A431, MDA-MB-468 and MCF-7 cells compared with wild-type HSV-1 17 þ , but in each of these cell types HSV1716Ing4 replication was significantly more efficient with yields similar to those of wild-type virus.
A hallmark of the attenuated HSV1716 phenotype in vitro is its inability to replicate in NIH 3T6 cells whereas these cells are fully permissive for HSV-1 17 þ replication. HSV1716Ing4 also completely failed to replicate in NIH 3T6 cells indicating that the growth advantage in human tumor cells provided by Ing4 is insufficient to overcome the effects of ICP34.5 gene ablation.
Improved efficiency of HSV1716 replication by Ing4 requires IE expression The replication of HSV1716 variants in which Ing4 expression was controlled by different promoters (see Figure 1 ) was analysed in A431, CP70, SKOV3 and SW480 cells (Figure 3) . The CMV promoter mediated Ing4 expression during immediate-early times, TK promoter at early times, and gC and UL38 promoters at late times of infection. Enhanced propagation of virus in all four cell types, as measured by progeny yields, was only observed with the CMV-Ing4 variant and differences with other variants were highly significant. The yields from gC-Ing4 or UL38-Ing4 propagation in A431, CP70, SKOV3 or SW480 cells were not significantly different from those of HSV1716. Yields from TK-Ing4 propagation in A431, CP70 or SKOV3 were also not significantly different from those of HSV1716, but although they were significantly higher in SW480 cells they were still significantly reduced compared with yields from CMV-Ing4 propagation in these cells. SW480 cells yields of Ing4delNLS or Ing4delC were significant lower than HSV1716 or gC-Ing4. Both Ing2 and Ing3 augmented HSV1716 progeny output in CP70 cells to levels that were similar to the yields from HSV1716Ing4 (Figure 4) , and all yields were significantly greater than unmodified HSV1716. In A431 cells, although yields from Ing2 and HSV1716Ing4 were similar, Ing3 yields were significantly lower that HSV1716Ing4 but still significantly greater than unmodified HSV1716. In SW480 or MDA-MB-468 cells, neither Ing2 nor Ing3 had an effect on HSV1716 propagation with yields that were not significantly different from those of unmodified HSV1716. In both SW480 and MDA-MB-468 cell lines, HSV1716Ing4 propagation yielded significantly more progeny than either Ing2 or Ing3 (Supplementary data).
HSV1716 propagation is enhanced in BHK, Vero and UVW cell lines constitutively expressing ING4 Stable, antibiotic-resistant BHK, Vero or UVW human glioma cell lines were created following transfection with either empty vector or vector expressing Ing4, and these were infected with either 10 (BHK) of 100 PFU (Vero/UVW) HSV1716. Intratumoral injection of nude mice bearing subcutaneous A431 tumor implants Groups of six mice bearing subcutaneous implants of human SCC A431 cells were given intratumoral injections on days 1 and 3 with either 1 Â 10 7 PFU of HSV1716Ing4 or HSV1716 or an equivalent volume of PBS, and tumor growth and survival were monitored. Figure 5a shows the average tumor volumes and demonstrated that treatment with HSV1716Ing4 reduced average tumor volumes compared with either no virus controls or HSV1716 treatment. Student's t-tests showed that the differences in tumor volumes between HSV1716Ing4 and HSV1716 were significant on days 4, 8, 12, 13, 14, 15 and 18. All of the mice that received HSV1716 had been killed by day 20 whereas 4/6 mice receiving HSV1716Ing4 were still alive. The mean day of death (±s.d.) for HSV1716 and HSV1716Ing4 were, respectively, 12 (±4) days and 20 ( ± 5) days, and the difference was significant (P ¼ 0.01) when compared using Student's t-test.
Intravenous injection of nude mice bearing subcutaneous tumor implants Intravenous injection of nude mice bearing subcutaneous human ovarian CP70 tumors with PBS (no virus) or with 1 Â 10 6 PFU HSV1716 or HSV1716Ing4 were performed on days 1 and 3, and tumor growth and survival were monitored. After intravenous injection, HSV1716Ing4 significantly reduced tumor growth compared with no virus controls or to HSV1716-injected animals ( Figure 5b ). Student's t-tests showed that tumor volumes between HSV1716Ing4-and HSV1716-treated animals were significantly different on days 22, 24 and 28. Mice that received HSV1716 were all killed by day 28 at which time 5/10 mice treated with HSV1716Ing4 were still alive. For HSV1716, the mean day of death ( ± s.d.) was 18 ± 4.5 days compared with 27 ± 9 days for HSV1716Ing4-treated mice, and using Student's t-test this difference was significant (P ¼ 0.03).
Intravenous injection of nude mice bearing subcutaneous human breast MDA-MB-468 tumors with PBS (no virus) or with 3.3 Â 10 6 PFU HSV1716 or HSV1716Ing4 were performed on days 1, 3 and 5, and tumor growth and survival were monitored. After intravenous injection, HSV1716Ing4 significantly reduced tumor growth compared with no virus controls or to HSV1716-injected animals ( Figure 5c ). Student's t-tests showed that tumor volumes for the HSV1716Ing4-treated animals were significantly smaller than those of HSV1716-treated animals on days 8, 10, 12, 15 and 17. The HSV1716-treated mice had all been killed by day 19, whereas, at this time, all the mice treated with HSV1716Ing4 were still alive. Indeed, when the experiment was stopped on day 33, 3/6 HSV1716Ing4-treated mice were still alive and their tumors had stopped growing. For HSV1716, the mean day of death ( ± s.d.) was 16.7 ± 1.5 days compared with 30.2 ± 3.8 days for HSV1716Ing4-treated mice and, using Student's t-test, this difference was highly significant (P ¼ 0.0001). Finally, groups of 10 mice with subcutaneous human SCC A431 tumors were intravenously injected with PBS (no virus) or with 1 Â 10 6 PFU HSV1716 or HSV1716Ing4 on days 1 and 3, and tumor growth and survival were monitored. After intravenous injection, HSV1716Ing4 significantly reduced tumor growth compared with no virus controls or to unmodified HSV1716 (Figure 5d ). Student's t-tests showed that the differences in tumor volumes between HSV1716Ing4 and HSV1716 were significant on days 8, 9, 10, 14, 15, 17 and 20. Mice receiving HSV1716 had a mean day of death of 14 ( ± 2) days, whereas mice receiving HSV1716Ing4 had a mean day of death of 19 (±6.5) days, and this difference was significant (Student's t-test, P ¼ 0.049). About 4 of the 10 mice receiving HSV1716Ing4 survived beyond day 20, at which time all the HSV1716-injected mice had been killed. Three tumors from each of the groups of mice were removed at the time of killing and, after mechanical homogenization, virus in equal volumes of tumor extracts was titrated. For HSV1716Ing4, 3.6 Â 10 6 , 2.7 Â 10 6 or 4.4 Â 10 6 PFU were extracted from tumors of mice killed on days 16, 18 and 18, respectively. Of the mice receiving HSV1716 by intravenous injection, 2/3 had no detectable virus (limit is 100 PFU ml À1 ) on days 16 and 17, suggesting that little or no HSV1716 localized to these xenografts and, for the third, 2.1 Â 10 3 PFU were extracted from the xenograft on day 17. No virus was detected in tumors from the PBS-injected mice. Thus, the amounts of virus detected in the HSV1716Ing4-infected tumors were at least 1000-fold greater than from the only HSV1716-infected tumor with detectable virus suggesting that, as with in vitro results, Ing4 must enhance progeny output.
In a separate experiment, three mice with A431 tumors were intravenously injected with 1 Â 10 6 PFU HSV1716Ing4 on days 1 and 3, and later killed on days 8, 14 and 30 (at which time the tumor had completely regressed); their organs and tumor tissue were harvested. Following mechanical homogenization and titration of equal volumes of tissue extracts, virus was isolated only from tumors on days 8 and 14 with no virus present at the residual tumor site on day 30 ( Figure 6 ). Using DNA extracted from these tissues and HSV gD and Ing4 PCR, evidence of viral DNA was only detected in tumor tissue on days 8 and 14 ( Figure 6 ). Thus, PCR and titration failed to detect virus in any tissue apart from tumor indicating that HSV1716Ing4 replication was restricted exclusively to tumors and retains the restricted replication phenotype of the parental HSV1716.
DISCUSSION
We report here on a novel activity for the human Ing4 tumor suppressor gene when overexpressed during infection of human tumor cells by the selectively replication-competent herpes simplex virus HSV1716. Compared with parental HSV1716, an HSV1716 variant that expressed Ing4 demonstrated enhanced oncolytic biopotency in vitro using a panel of 10 different human cancer cell lines and in vivo in 3 different mouse xenograft models. Expression of Ing4 during HSV1716 infection of human cancer cell lines conferred a growth advantage to the virus by augmenting the number of infectious progeny produced from each cell. Thus, a greater number of progeny were released from cells infected with HSV1716Ing4, improving the propagation of the virus and enhancing its ability to destroy tumors. This enhancement to HSV1716 replication is a direct consequence of Ing4 expression as first, the replicative boost was lost in two viruses expressing mutant forms of Ing4 that lacked the C-terminus or the conserved NLS of the protein. Second, enhanced replication required IE expression of Ing4 as the effect was absent from three almost identical Ing4-expressing viruses differing only in the promoters controlling Ing4 expression. Third, as with Ing4, two other members of the Ing family, Ing2 and Ing3, were able to boost progeny production in CP70 and A431 cells, but failed to augment virus propagation in MDA-MB-468 and SW480 cells. Finally, unmodified HSV1716 replication was enhanced in cell lines that constitutively expressed Ing4.
The replication efficiencies of HSV-1 17 þ , HSV1716 and HSV1716Ing4, as measured by the yields of progeny, varied among the cell types analyzed in this study. MDA-MB-361, Ovcar-3, PC3 and SW480 cells supported replication of HSV-1 17 þ and HSV1716 equally although the output varied between cell lines. In each cell type, the expression of Ing4 significantly stimulated progeny production. Compared with wild-type, HSV1716 replication in A2780, SKOV3, CP70, A431, MDA-MB-468 and MCF-7 cells was impaired but crucially, in each of these lines, HSV1716Ing4 replication efficiency attained wild-type or almost wild-type levels. Thus, in human cancer cell lines in which HSV1716 replication is inefficient or impaired, Ing4 enhanced progeny output. Importantly, in NIH 3T6 cells, which support wild-type but not HSV1716 replication, HSV1716Ing4 failed to replicate and, therefore, despite the growth advantage conferred in vitro in human cancer cells by Ing4 expression, HSV1716Ing4 maintained the HSV1716 phenotype. The failure of HSV1716Ing4 to replicate in NIH 3T6 cells suggests that the Ing4 stimulatory mechanism is unable to overcome the requirement for ICP34.5 in the infected cell.
HSV1716Ing4 demonstrated significant inhibition of tumor growth and prolonged survival times following intratumoral injection of nude mice with subcutaneous A431 tumor implants when compared with unmodified HSV1716. Intravenous injection of HSV1716Ing4 also reduced tumor growth and prolonged survival compared with intravenously injected HSV1716 in three different xenograft models. As with the in vitro studies, more virus was detected in the HSV1716Ing4-infected tumors compared with the HSV1716-infected tumor and, therefore, expression of Ing4 must have improved the efficiency of virus replication. Consequentially, more infectious progeny were produced per infected tumor cell and this enhanced efficacy. Previous studies, albeit in immunocompetent rats, have shown that only 0.001% of the intravenously injected oncolytic HSV mutant hrR3 lodged in the tumor 24 h after administration and, assuming that this provides a reasonable approximation for nude mice, then, of the 2 Â 10 6 PFU administered intravenously, only 20 PFU are likely to reach the tumor. 27 It is possible therefore, at this low level of bioavailability, that virus may not localize to the xenografts in some mice. However, assuming similar biodistribution for HSV1716 and HSV1716Ing4 then HSV1716Ing4 replicated significantly better in A431 SCC tumor implants than HSV1716 and enhanced survival. Thus, during HSV1716Ing4 infection, Ing4 conditions the cell to provide a better environment for replication. Importantly, this enhancement to replication efficiency by Ing4 did not compromise the HSV1716 phenotype in vivo as no toxicity was observed, and virus DNA or infectious viruses were exclusively detected in tumor tissue.
The Ing family of proteins are tumor suppressors frequently downregulated in many types of cancers but the effects of their reduced expression in carcinogenesis have yet to be elucidated. Ing proteins associate with modified histones and with histone acetyl transferases (HAT) and histone deacetlylases (HDAC) via their PHD domains and these interactions probably account for their abilities to regulate gene expression.
1,2 The highly conserved PHD domain contains a C4HC3 zinc finger motif and interacts specifically with trimethylated lysine 4 of histone H3, and the requisite nuclear localization is probably mediated via the central NLS conserved in Ing2, Ing3 and Ing4 (see Figure 1) . Although varying in molecular sizes, Ing2, Ing3 and Ing4 also share conserved N-terminal leucine zipper motifs and a novel conserved region that may participate in HAT/HDAC interactions.
1,2 Ing proteins are promiscuous in their choice of binding partners and despite the highly conserved features, individual family members display diverse repertoires of interacting proteins.
1,2,11 For example, Ing2 interacts with mSin3-HDAC1/2, Ing3 binds TIP60 (HAT complex) and Ing4 interacts with HBO1 (HAT complex) suggesting that individual Ing family members display different interpretations of the 'histone code'. 28 Ing4 and Ing2 but not Ing3 bind p300/p53, Ing4 interacts with Liprin 1-alpha, and HIF prolylhydroxylase and Ing2 also associates with phosphatidylinositol 5-phosphate and may function as a nuclear receptor for this molecule. 29--33 Differences in binding partners may explain the inabilities of either Ing2 or Ing3 to reproduce identically the effects of Ing4 on HSV1716 replication in all cell types. Indeed, this incomplete mimicry among Ing family members along with the variability of the Ing4 boost to propagation in different cell lines suggests that the Ing4 mechanism of action during HSV1716 replication is probably complex, multifactorial and perhaps celltype dependent.
Potentially, Ing4 and, to a lesser extent, Ing2 or Ing3, produced during the IE phase of HSV1716 replication, activates/represses a subset of cellular genes via histone interactions to create a cellular environment more conducive to virus replication. Interestingly, HDAC inhibitors have been reported to enhance the efficacy of oncolytic HSV by significantly increasing the yield of viral progeny in cultured glioma cells. 34 Possibly, Ing4 association with modified histones mimics the action of HDAC inhibitors and is responsible for the enhanced efficacy of HSV1716ING4. However, HDAC inhibitors were most effective at enhancing HSV progeny output when administered before infection whereas concomitant treatment had a negative effect via inhibition of viral DNA replication and late gene expression. As Ing4 is required during HSV1716Ing4 IE times, it seems unlikely that Ing4 mimicry of HDAC inhibitors is solely responsible for improved viral replication. Figure 6 . Biodistribution of HSV1716Ing4 in nude mice with subcutaneous A431 xenografts after intravenously injected with 1 Â 10 6 PFU (plaque-forming unit) HSV1716ING4 on days 1 and 3. Mice were killed on days 8, 14 and 30 (at which time the tumor in this mouse had completely regressed), and their organs and tumor tissue were harvested. For titration, values are Â 10 6 PFU ml À1 and for PCR, 0 ¼ no signal detectable, 1 ¼ weak signal, 2 ¼ medium signal and 3 ¼ strong signal. Both PCRs are semiquantitative, the HSV gD PCR is highly sensitive and produces weak or medium signals for trace or very low levels of HSV DNA.
NFk-B is constitutively active in many cancer cells and the loss of the Ing4-mediated restriction of NF-kB activity may facilitate tumorigenesis. 6 In addition, numerous intracellular signaling pathways are activated by viral invasion leading to the coordinated response of cellular genes whose protein products aim to mitigate viral replication and NFk-B is associated with this innate cellular response. 35--37 Ing4 attenuates NF-kB activity at the promoters of target genes and therefore the suppression of NFkB-mediated expression of cellular antiviral genes in human cancer cells may enhance HSV1716 replication. 38 However, although HSV infection activates NF-kB, the virus has usurped this cellular defence and grows optimally in cells with activated NF-kB. 39--41 Suppression of NF-kB and the cellular antiviral response by Ing4 is therefore probably not responsible for the augmented replication of HSV1716Ing4 in human tumor cells.
Ectopic Ing4 overexpression has been shown to cause cell cycle arrest in a p53-dependent manner and induce apoptosis, and it is possible that these effects act to enhance progeny production during HSV1716Ing4 infection. 42 However, HSV infection per se induces complex perturbations of the cell cycle and blocks apoptosis during early times of the lytic cycle. 43 In addition, the HSV replication cycle lasts between 18--24 h with the virus assuming control of cellular processes during the IE stage of infection and it is at this time that Ing4 has, most probably, direct effects on virus gene expression and replication. It is unlikely that virally expressed Ing4 will be able to influence the cell cycle or induce apoptosis against the background of rampant lytic infection.
Interestingly, modified histones have been reported to interact with the HSV-1 genome during IE times of infection at the promoter regions of all classes of genes and such recruitment apparently has an active role in efficient HSV-1 replication. 44, 45 As Ing4 interacts with both modified histones and HATs, its overexpression during IE times of virus infection may stimulate these interactions and directly improve virus replication via enhanced gene expression. The interaction of Ing4 with histones is mediated via its C-terminal PHD domain and requires nuclear localization, and the absence of augmented progeny production in HSV1716 variants expressing mutant Ing4 proteins lacking these regions suggests that histone interactions are a key component to Ing4-mediated enhancement of HSV1716 replication. However, the cell-type variability in the magnitude of the replicative boost and the failures of Ing2 or Ing3 to substitute fully for Ing4 is suggestive of more complex mechanisms of action that may vary among cell types. Further studies into Ing4 stimulation of HSV1716 replication are currently ongoing; however, our results clearly demonstrate that Ing4 is an exceptionally useful adjunct to HSV1716 oncolysis and the use of ICP34.5 null HSV expressing Ing4 in the clinic should be considered.
